You are here

osteoporosis

Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning

Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning

Xconomy

Flag link:

Radius plans to cut loose oncology assets

Radius plans to cut loose oncology assets

Fierce Biotech

endocrine disorders

Flag link:

Merck seeks partner for disease-modifying osteoarthritis drug

Merck seeks partner for disease-modifying osteoarthritis drug

PM Live

Flag link:

FDA approves Pfenex's osteoporosis therapy

FDA approves Pfenex's osteoporosis therapy

Yahoo/Reuters

Flag link:

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Pharmaforum

Flag link:

Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Pharmaceutical Business Review

clinical trials

Flag link:

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Amgen/UCB hit another Evenity hurdle, as European regulators fail to back the osteoporosis drug

Endpoints

Flag link:

Consumer watchdog petitions FDA for black box warning on Amgen's Prolia

Consumer watchdog petitions FDA for black box warning on Amgen's Prolia

Fierce Pharma

spinal fractures

Flag link:

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost

Endpoints

Flag link:

FDA approves Evenity for osteoporosis

FDA approves Evenity for osteoporosis

BioCentury

Flag link:

Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote

Amgen's once-dismissed osteoporosis drug Evenity 'back in the game' after rosy FDA panel vote

Fierce Pharma

advisory panels

Flag link:

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

FDA staff largely unfazed by CV signal in Amgen osteoporosis drug trials

Endpoints

clinical trials

Flag link:

Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead

Amgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA — but big hurdles lie ahead

Endpoints

Flag link:

Radius Health Initiates Phase III Trial of Osteoporosis Injection Drug for Males

Radius Health Initiates Phase III Trial of Osteoporosis Injection Drug for Males

CP Wire

clinical trials

Flag link:

Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag

Amgen rolls new Prolia osteoporosis ads, just weeks after next-gen Evenity hits a snag

Fierce Pharma

Flag link:

Payer coverage boosts Radius' Tymlos

Payer coverage boosts Radius' Tymlos

BioPharma Dive

Express Scripts

Flag link:

Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo

Radius' Tymlos gets another big break as Express Scripts boots Lilly's Forteo

Fierce Pharma

Express Scripts

Flag link:

An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape

An Endocrinologist Explains Her View Of Tymlos And The Osteoporosis Landscape

Seeking Alpha

Flag link:

FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO

FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO

Endpoints

Flag link:

Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug

Amgen's romosozumab red flag on heart safety means a boost for new Radius bone drug

Fierce Pharma

Flag link:

Pages